310 related articles for article (PubMed ID: 21477702)
1. [Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient].
Alvarez-Lerma F; Gracia-Arnillas MP
Med Clin (Barc); 2010 Dec; 135 Suppl 3():29-35. PubMed ID: 21477702
[TBL] [Abstract][Full Text] [Related]
2. [Clinical experience with daptomycin use in Spain. Global findings from EU-CORE database].
Almirante B
Med Clin (Barc); 2010 Dec; 135 Suppl 3():23-8. PubMed ID: 21477701
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of treatments used in infections caused by gram-positive multiresistant cocci in critically ill patients admitted to the ICU].
Álvarez-Lerma F; Palomar Martínez M; Olaechea Astigarraga P; Insausti Ordeñana J; López Pueyo MJ; Gracia Arnillas MP; Gimeno Costa R; Seijas Betolaza I
Rev Esp Quimioter; 2012 Mar; 25(1):65-73. PubMed ID: 22488544
[TBL] [Abstract][Full Text] [Related]
4. [Role of daptomycin in the treatment of infections in patients with hematological malignancies].
Salavert M; Calabuig E
Med Clin (Barc); 2010 Dec; 135 Suppl 3():36-47. PubMed ID: 21477703
[TBL] [Abstract][Full Text] [Related]
5. [The EUCORE registry: objectives and general results].
Cercenado E; Pachón J
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():3-9. PubMed ID: 22541969
[TBL] [Abstract][Full Text] [Related]
6. [Daptomycin therapy in patients with bacteremia].
Llinares P; Iribarren JA
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():17-25. PubMed ID: 22541971
[TBL] [Abstract][Full Text] [Related]
7. [Impact of primary and intravascular catheter-related bacteremia due to coagulase-negative staphylococci in critically ill patients].
Olaechea PM; Alvarez-Lerma F; Palomar M; Insausti J; López-Pueyo MJ; Martínez-Pellús A; Cantón ML;
Med Intensiva; 2011 May; 35(4):217-25. PubMed ID: 21130534
[TBL] [Abstract][Full Text] [Related]
8. Use of linezolid in critically ill patients admitted to intensive care units.
Rodríguez O; Alvarez F; Oltra R; Cereijo E; Latorre MM; Martínez H;
Rev Esp Quimioter; 2009 Jun; 22(2):68-75. PubMed ID: 19554485
[TBL] [Abstract][Full Text] [Related]
9. [Safety of daptomycin in patients with renal impairment].
Azanza JR; Quetglas EG
Med Clin (Barc); 2010 Dec; 135 Suppl 3():55-9. PubMed ID: 21477705
[TBL] [Abstract][Full Text] [Related]
10. [New treatment option for gram-positive infections in critically ill patients - overview over linezolid].
Krueger WA; Unertl KE
Anasthesiol Intensivmed Notfallmed Schmerzther; 2002 Apr; 37(4):199-204. PubMed ID: 11967745
[TBL] [Abstract][Full Text] [Related]
11. Safety and clinical outcomes when utilizing high-dose (> or =8 mg/kg) daptomycin therapy.
Moise PA; Hershberger E; Amodio-Groton MI; Lamp KC
Ann Pharmacother; 2009 Jul; 43(7):1211-9. PubMed ID: 19584384
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.
Seaton RA; Menichetti F; Dalekos G; Beiras-Fernandez A; Nacinovich F; Pathan R; Hamed K
Adv Ther; 2015 Dec; 32(12):1192-205. PubMed ID: 26610384
[TBL] [Abstract][Full Text] [Related]
13. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.
Gonzalez-Ruiz A; Gargalianos-Kakolyris P; Timerman A; Sarma J; José González Ramallo V; Bouylout K; Trostmann U; Pathan R; Hamed K
Adv Ther; 2015 Jun; 32(6):496-509. PubMed ID: 26108157
[TBL] [Abstract][Full Text] [Related]
14. [Antibiotic treatment of enterococcal infections in gastroenterology with daptomycin - first experiences from the EU-CORE registry study (European Cubicin® Outcomes Registry and Experience)].
Lübbert C; Wilhelms D; Worlitzsch D; Ettrich TJ; Behl S; Seufferlein T
Z Gastroenterol; 2012 Apr; 50(4):373-81. PubMed ID: 22430297
[TBL] [Abstract][Full Text] [Related]
15. Multidrug-resistant gram-positive infections in patients with ventricular assist devices: the role of daptomycin.
Beiras-Fernandez A; Kur F; Kiefer S; Sodian R; Schmoeckel M; Weis M; Reichart B; Weis F
Transplant Proc; 2009; 41(6):2589-91. PubMed ID: 19715980
[TBL] [Abstract][Full Text] [Related]
16. High-dose daptomycin for treatment of complicated gram-positive infections: a large, multicenter, retrospective study.
Kullar R; Davis SL; Levine DP; Zhao JJ; Crank CW; Segreti J; Sakoulas G; Cosgrove SE; Rybak MJ
Pharmacotherapy; 2011 Jun; 31(6):527-36. PubMed ID: 21923436
[TBL] [Abstract][Full Text] [Related]
17. [Role of daptomycin in the empirical and directed therapy of infections caused by Gram-positive bacteria in the critically ill patient].
Garnacho-Montero J; Amaya-Villar R; Gómez-Grande ML; Jerez V; Lorente-Ramos L; Loza A; Martínez A; Pozo JC; Sierra R; Pomares J; de la Torre MV; Ortiz C
Rev Esp Quimioter; 2011 Mar; 24(1):13-24. PubMed ID: 21412665
[TBL] [Abstract][Full Text] [Related]
18. [Daptomycin in diabetic patients].
Montejo M
Enferm Infecc Microbiol Clin; 2012 Feb; 30 Suppl 1():54-8. PubMed ID: 22541977
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes of patients receiving daptomycin for the treatment of Staphylococcus aureus infections and assessment of clinical factors for daptomycin failure: a retrospective cohort study utilizing the Cubicin Outcomes Registry and Experience.
Sakoulas G; Brown J; Lamp KC; Friedrich LV; Lindfield KC
Clin Ther; 2009 Sep; 31(9):1936-45. PubMed ID: 19843483
[TBL] [Abstract][Full Text] [Related]
20. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.
Seaton RA; Gonzalez-Ruiz A; Cleveland KO; Couch KA; Pathan R; Hamed K
Ann Clin Microbiol Antimicrob; 2016 Mar; 15():18. PubMed ID: 26976128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
